FDA’s capacity to inspect overseas drug makers under scrutiny

By Hillel Aron FairWarning With the U.S. increasingly dependent on foreign manufacturers for prescription and generic drugs, the Food and Drug Administration’s problem-plagued efforts to inspect overseas plants is under growing scrutiny. A recent report by the Government Accountability Office has raised serious concerns about the FDA’s foreign inspection program and whether it’s allowing overseas drug makers […]